265 related articles for article (PubMed ID: 30717485)
1. Immunogenicity and Efficacy of a Novel Multi-Antigenic Peptide Vaccine Based on Cross-Reactivity between Feline and Human Immunodeficiency Viruses.
Sahay B; Aranyos AM; Mishra M; McAvoy AC; Martin MM; Pu R; Shiomitsu S; Shiomitsu K; Dark MJ; Sanou MP; Roff SR; Rathore MH; Yamamoto JK
Viruses; 2019 Feb; 11(2):. PubMed ID: 30717485
[TBL] [Abstract][Full Text] [Related]
2. Utilization of Feline ELISpot to Evaluate the Immunogenicity of a T Cell-Based FIV MAP Vaccine.
Sahay B; Aranyos AM; McAvoy A; Yamamoto JK
Methods Mol Biol; 2018; 1808():197-219. PubMed ID: 29956186
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 p24 vaccine protects cats against feline immunodeficiency virus infection.
Coleman JK; Pu R; Martin M; Sato E; Yamamoto JK
AIDS; 2005 Sep; 19(14):1457-66. PubMed ID: 16135898
[TBL] [Abstract][Full Text] [Related]
4. Immunization-induced decrease of the CD4+:CD8+ ratio in cats experimentally infected with feline immunodeficiency virus.
Lehmann R; von Beust B; Niederer E; Condrau MA; Fierz W; Aubert A; Ackley CD; Cooper MD; Tompkins MB; Lutz H
Vet Immunol Immunopathol; 1992 Dec; 35(1-2):199-214. PubMed ID: 1363009
[TBL] [Abstract][Full Text] [Related]
5. An initial examination of the potential role of T-cell immunity in protection against feline immunodeficiency virus (FIV) infection.
Aranyos AM; Roff SR; Pu R; Owen JL; Coleman JK; Yamamoto JK
Vaccine; 2016 Mar; 34(12):1480-8. PubMed ID: 26802606
[TBL] [Abstract][Full Text] [Related]
6. Recombinant FeLV vaccine: long-term protection and effect on course and outcome of FIV infection.
Hofmann-Lehmann R; Holznagel E; Aubert A; Ossent P; Reinacher M; Lutz H
Vet Immunol Immunopathol; 1995 May; 46(1-2):127-37. PubMed ID: 7618252
[TBL] [Abstract][Full Text] [Related]
7. Efficacy evaluation of prime-boost protocol: canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats.
Tellier MC; Pu R; Pollock D; Vitsky A; Tartaglia J; Paoletti E; Yamamoto JK
AIDS; 1998 Jan; 12(1):11-8. PubMed ID: 9456250
[TBL] [Abstract][Full Text] [Related]
8. Lessons Learned in Developing a Commercial FIV Vaccine: The Immunity Required for an Effective HIV-1 Vaccine.
Sahay B; Yamamoto JK
Viruses; 2018 May; 10(5):. PubMed ID: 29789450
[TBL] [Abstract][Full Text] [Related]
9. Conserved epitopes on HIV-1, FIV and SIV p24 proteins are recognized by HIV-1 infected subjects.
Roff SR; Sanou MP; Rathore MH; Levy JA; Yamamoto JK
Hum Vaccin Immunother; 2015; 11(6):1540-56. PubMed ID: 25844718
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic utility of CD4%:CD8 low% T-lymphocyte ratio to differentiate feline immunodeficiency virus (FIV)-infected from FIV-vaccinated cats.
Litster A; Lin JM; Nichols J; Weng HY
Vet Microbiol; 2014 Jun; 170(3-4):197-205. PubMed ID: 24559863
[TBL] [Abstract][Full Text] [Related]
11. Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates.
Pu R; Coleman J; Omori M; Arai M; Hohdatsu T; Huang C; Tanabe T; Yamamoto JK
AIDS; 2001 Jul; 15(10):1225-37. PubMed ID: 11426067
[TBL] [Abstract][Full Text] [Related]
12. Impaired T-cell priming and proliferation in cats infected with feline immunodeficiency virus.
Bishop SA; Williams NA; Gruffydd-Jones TJ; Harbour DA; Stokes CR
AIDS; 1992 Mar; 6(3):287-93. PubMed ID: 1348945
[TBL] [Abstract][Full Text] [Related]
13. Protection against FIV challenge infection by genetic vaccination using minimalistic DNA constructs for FIV env gene and feline IL-12 expression.
Boretti FS; Leutenegger CM; Mislin C; Hofmann-Lehmann R; König S; Schroff M; Junghans C; Fehr D; Huettner SW; Habel A; Flynn JN; Aubert A; Pedersen NC; Wittig B; Lutz H
AIDS; 2000 Aug; 14(12):1749-57. PubMed ID: 10985311
[TBL] [Abstract][Full Text] [Related]
14. Involvement of gag- and env-specific cytotoxic T lymphocytes in protective immunity to feline immunodeficiency virus.
Flynn JN; Beatty JA; Cannon CA; Stephens EB; Hosie MJ; Neil JC; Jarrett O
AIDS Res Hum Retroviruses; 1995 Sep; 11(9):1107-13. PubMed ID: 8554908
[TBL] [Abstract][Full Text] [Related]
15. Dual-subtype vaccine (Fel-O-Vax FIV) protects cats against contact challenge with heterologous subtype B FIV infected cats.
Kusuhara H; Hohdatsu T; Okumura M; Sato K; Suzuki Y; Motokawa K; Gemma T; Watanabe R; Huang C; Arai S; Koyama H
Vet Microbiol; 2005 Jul; 108(3-4):155-65. PubMed ID: 15899558
[TBL] [Abstract][Full Text] [Related]
16. Vaccination of cats with attenuated feline immunodeficiency virus proviral DNA vaccine expressing gamma interferon.
Gupta S; Leutenegger CM; Dean GA; Steckbeck JD; Cole KS; Sparger EE
J Virol; 2007 Jan; 81(2):465-73. PubMed ID: 17079309
[TBL] [Abstract][Full Text] [Related]
17. MHC-restricted protection of cats against FIV infection by adoptive transfer of immune cells from FIV-vaccinated donors.
Pu R; Omori M; Okada S; Rine SL; Lewis BA; Lipton E; Yamamoto JK
Cell Immunol; 1999 Nov; 198(1):30-43. PubMed ID: 10612649
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with vif-deleted feline immunodeficiency virus provirus, GM-CSF, and TNF-alpha plasmids preserves global CD4 T lymphocyte function after challenge with FIV.
Maksaereekul S; Dubie RA; Shen X; Kieu H; Dean GA; Sparger EE
Vaccine; 2009 Jun; 27(28):3754-65. PubMed ID: 19464559
[TBL] [Abstract][Full Text] [Related]
19. Effects of incidental infections and immune activation on disease progression in experimentally feline immunodeficiency virus-infected cats.
Reubel GH; Dean GA; George JW; Barlough JE; Pedersen NC
J Acquir Immune Defic Syndr (1988); 1994 Oct; 7(10):1003-15. PubMed ID: 7916048
[TBL] [Abstract][Full Text] [Related]
20. Env-specific CTL predominate in cats protected from feline immunodeficiency virus infection by vaccination.
Flynn JN; Keating P; Hosie MJ; Mackett M; Stephens EB; Beatty JA; Neil JC; Jarrett O
J Immunol; 1996 Oct; 157(8):3658-65. PubMed ID: 8871667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
